The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Arseniy Shabashvili - Guggenheim Partners, LLC - Analyst
: Hi. Congrats on all the progress in 2024.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 18, 2025 / 8:30PM, ABSI.OQ - Q4 2024 Absci Corp Earnings Call
We have a question on 201, given the data that you (inaudible), clinically, how are you thinking about the design and end point for the planned
phase 1?
Question: Arseniy Shabashvili - Guggenheim Partners, LLC - Analyst
: Thank you. That's very helpful.
And, maybe, one more on the large pharma partnership that you're hoping to secure in 2025. Can you share, maybe just on the high level, which
therapeutic areas the modalities discussions are focusing on? Maybe, what companies are interested in it? And, maybe, where they recognize your
capabilities and your (technical difficulty)?
Question: Arseniy Shabashvili - Guggenheim Partners, LLC - Analyst
: Thank you.
Question: Vikram Purohit - Morgan Stanley & Co LLC - Analyst
: Hi. Good afternoon. Thanks for taking our questions.
We have two. First, on 101, we just wanted to revisit expectations for the readout in the second half of the year. I was just curious to see any updated
thoughts you might have around the size of the data set, the scope of the data set we'll be receiving? Just your current view on what you would
consider a really strong outcome, here.
And, then, secondly, I think you mentioned that you're working on a bispecific that addresses TL1A, in part. I was just curious on what the next
steps there might be? What you think the future for that program could be? Whether that could be something that's eventually partnered alongside
101 or would that be a separate effort you want to hold on to, for a longer time point?
Thanks.
Question: Gil Blum - Needham & Company, LLC - Analyst
: Good afternoon. Thanks for taking our questions.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 18, 2025 / 8:30PM, ABSI.OQ - Q4 2024 Absci Corp Earnings Call
One, relating to the planned pharma partnership, did some of the achievements that you, guys, demonstrated -- binding to the caldera region of
HIV -- did that play into your pharma discussions?
And I have a follow-up.
Question: Gil Blum - Needham & Company, LLC - Analyst
: Big deal.
Question: Gil Blum - Needham & Company, LLC - Analyst
: Okay. That's very helpful.
And as it relates to this bispecific lead, you mentioned, for IBD. What kind of dynamic should we imagine, here, with ABS-101?
I mean there are other companies in the space that are really taking lead on this combo approach. Is this what we're thinking of, here? Or is this
something really completely different?
Thank you.
Question: Gil Blum - Needham & Company, LLC - Analyst
: Great. Very helpful. Thanks for taking our questions.
Question: Debanjana Chatterjee - Jones Research - Analyst
: Thanks for taking my question.
Given the recent positive data from Sanofi and Teva's duvakitug in ulcerative colitis colitis, particularly the strong efficacy and low ADA rates in
patients, how is Absci positioning its anti-TL1A Absci to compete? To what extent does this raise the bar, in terms of, like, clinical performance or
commercial potential?
Question: Debanjana Chatterjee - Jones Research - Analyst
: Okay. Thanks for that.
Question: Swayampakula Ramakanth - H.C. Wainwright & Co. - Analyst
: Thank you. This is RK, from H.C. Wainwright. Good afternoon, Sean, and Zach, and Alex.
A lot of my questions on the pipeline have been already asked. But, in the time that you spent generating this pipeline, how much of that data has
allowed you to expand the pipeline? Are you able to take it back into your model, into your AI models? Are you able to strengthen it? What sort of
Question: Swayampakula Ramakanth - H.C. Wainwright & Co. - Analyst
: Thank you, both, for taking the questions.
|
